As global markets exhibit mixed reactions to recent economic data, with some indices showing resilience amidst unexpected inflation trends, the Swedish stock market presents a unique landscape for investors seeking value. In this context, identifying stocks that appear undervalued relative to their intrinsic estimates becomes particularly compelling, offering potential opportunities in a fluctuating market environment.
Top 10 Undervalued Stocks Based On Cash Flows In Sweden
Overview: Absolent Air Care Group AB specializes in designing, developing, selling, installing, and maintaining air filtration units with a market capitalization of approximately SEK 4.08 billion.
Operations: The company generates revenue primarily through two segments: Industrial, which brought in SEK 1.12 billion, and Commercial Kitchen, contributing SEK 289.38 million.
Estimated Discount To Fair Value: 14.2%
Absolent Air Care Group, with a current trading price of SEK 360, is positioned below our calculated fair value of SEK 419.78. This indicates a moderate undervaluation based on discounted cash flows. Recent financial results show an increase in net income and earnings per share compared to the previous year, alongside a dividend hike. Despite this positive performance, revenue growth projections (9.6% annually) and forecasted earnings growth (17% annually) suggest potential yet are not exceedingly high compared to broader market expectations.
Overview: Sweco AB (publ) is a global provider of architecture and engineering consultancy services, with a market capitalization of approximately SEK 59.71 billion.
Operations: Sweco's revenue is generated from various regional segments, with Sweden contributing SEK 8.74 billion, Norway SEK 3.50 billion, Belgium SEK 3.97 billion, Denmark SEK 3.24 billion, Finland SEK 3.67 billion, the Netherlands SEK 3.00 billion, and Germany & Central Europe SEK 2.71 billion.
Estimated Discount To Fair Value: 19.2%
Sweco, priced at SEK 166, trades below the calculated fair value of SEK 205.43, reflecting a modest undervaluation based on discounted cash flows. The company's return on equity is expected to be strong at 20.4% in three years. While Sweco's revenue growth (6.2% annually) is not rapid, it surpasses the Swedish market average (1.8%). Recent earnings have improved significantly with net income rising to SEK 540 million in Q2 from SEK 357 million year-over-year, alongside securing a substantial contract worth around SEK 400 million with the Swedish Transport Administration for railway expansion projects.
Overview: Xvivo Perfusion AB is a medical technology firm based in Sweden, specializing in the development and marketing of machines and solutions for organ assessment and preservation before transplantation, operating globally with a market cap of SEK 16.95 billion.
Operations: The company generates revenue primarily through three segments: Services (SEK 83.39 million), Thoracic (SEK 451.49 million), and Abdominal (SEK 163.85 million).
Estimated Discount To Fair Value: 25.5%
Xvivo Perfusion, with a current price of SEK 538, is considered undervalued against a fair value of SEK 722.14, showing a significant discount based on discounted cash flows. Despite its low forecasted return on equity at 10.5% in three years, the company's earnings and revenue growth projections are robust. Earnings have surged by 344% over the past year and are expected to grow annually by 36.88%. Recent financials confirm strong performance with Q2 net income reaching SEK 27.19 million from SEK 6.89 million year-over-year, supported by sales growth from SEK 154.57 million to SEK 210.35 million in the same period.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OM:ABSO OM:SWEC B and OM:XVIVO.
